TrialBlood advances2021

Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T-cell lymphoma: final data.

Steven M Horwitz et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.